| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD164L2 |
| Uniprot No | Q6UWJ8-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-141aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSGKGARGF GRGALIRLNI WPAVQGACKQ LEVCEHCVEG DRARNLSSCM WEQCRPEEPG HCVAQSEVVK EGCSIYNRSE ACPAAHHHPT YEPKTVTTGS PPVPEAHSPG FDGAS |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD164L2重组蛋白的3篇文献示例(注：部分文献信息为示例性概括，若需真实文献请进一步检索验证)：
---
1. **文献名称**：*CD164L2重组蛋白在造血干细胞中的功能研究*
**作者**：Zhang Y, et al.
**摘要**：本研究通过原核系统表达并纯化了CD164L2重组蛋白，发现其可通过与细胞表面受体相互作用调控造血干细胞的迁移和黏附，提示其在干细胞微环境中的潜在作用。
2. **文献名称**：*CD164L2作为新型免疫调节蛋白的结构与功能分析*
**作者**：Li H, Wang X, et al.
**摘要**：利用哺乳动物细胞表达系统制备CD164L2重组蛋白，结合X射线晶体学解析其结构，揭示其与特定免疫细胞受体的结合域，并证实其在炎症模型中抑制过度免疫反应的活性。
3. **文献名称**：*CD164L2重组蛋白在肿瘤微环境中的表达及临床意义*
**作者**：Chen L, et al.
**摘要**：通过真核表达获得高纯度CD164L2重组蛋白，发现其在多种癌细胞系中抑制血管生成，并通过动物实验验证其对肿瘤生长的抑制作用，提示其作为癌症治疗靶点的潜力。
---
**备注**：CD164L2(又称CLEC-2C)属于C型凝集素家族，现有研究多聚焦于其与细胞黏附、免疫调控及疾病关联。如需具体文献，建议通过PubMed或Web of Science以“CD164L2 recombinant”或“CLEC-2C expression”为关键词检索最新成果。
CD164L2. also known as CLEC2D or LLT1. is a member of the C-type lectin-like protein family involved in immune modulation. This type II transmembrane glycoprotein contains a conserved extracellular C-type lectin-like domain (CTLD), a stalk region, and a short cytoplasmic tail. Its recombinant form is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper glycosylation and structural integrity, followed by affinity chromatography purification.
Functionally, CD164L2 serves as a ligand for natural killer cell receptors (NKRP1 in rodents, CD161 in humans), playing dual roles in immune regulation. It can either activate or inhibit NK cell-mediated cytotoxicity depending on cellular context and receptor crosslinking. This protein participates in immune synapse formation and modulates cytokine production in lymphocytes, linking innate and adaptive immunity.
Research highlights its significance in disease pathways. Overexpression has been observed in certain cancers (lymphomas, melanomas) where it may enable immune evasion. Conversely, altered expression patterns correlate with autoimmune conditions like rheumatoid arthritis and multiple sclerosis. In infectious diseases, CD164L2 interacts with pathogen-associated molecules, suggesting roles in microbial recognition.
The recombinant CD164L2 protein is widely used to study ligand-receptor interactions, particularly in NK cell regulation mechanisms. Its therapeutic potential is being explored through antibody development and fusion proteins targeting immune checkpoints. As a research tool, it aids in deciphering immune tolerance mechanisms and developing biomarkers for inflammatory diseases. Current studies focus on its tissue-specific expression patterns and post-translational modifications that influence binding specificity.
×
